• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 7th July 2016

Dr Francois Maignen joins the OHE team as Head of Operational Research and Data Analysis

OHE is pleased to announce that Dr Francois Maignen has joined the team as Head of Operational Research and Data Analysis. Francois’s principal areas of expertise are in the clinical development (methodology of clinical trials) and regulation of medicines for…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Francois

OHE is pleased to announce that Dr Francois Maignen has joined the team as Head of Operational Research and Data Analysis. Francois’s principal areas of expertise are in the clinical development (methodology of clinical trials) and regulation of medicines for human use.

OHE is pleased to announce that Dr Francois Maignen has joined the team as Head of Operational Research and Data Analysis. Francois’s principal areas of expertise are in the clinical development (methodology of clinical trials) and regulation of medicines for human use.

 

Francois worked at the European Medicines Agency for 15 years. Here he gathered extensive experience in clinical safety and regulation of medicines in the EU (mainly oncology and cardiovascular and similar biological medicinal products in collaboration with the Committee for Medicines for Human Use), as well as extensive knowledge of pharmacovigilance (detection of new safety signals for centrally authorised medicinal products in collaboration with the Pharmacovigilance Risk Assessment Committee). He was directly involved in the implementation of the EU database of individual case safety reports (EudraVigilance).

As a statistician, Francois has contributed to the implementation of statistical methods of signal detection and analysis in EudraVigilance. He has conducted and supervised pharmacoepidemiology and data mining studies on the statistical aspects of pharmacovigilance statistical signal detection via the PROTECT IMI public private partnership research project.

He has mainly worked on the use of the time to onset of adverse drug reactions as a potential approach to signal detection and on the masking effect of measures of disproportionality analysis1,2,3. Francois has also actively contributed to international harmonisation activities with the Council for International Organizations of Medical Sciences (CIOMS VII (development safety update report) and VIII (signal management)). His work on the exchange of information signals between Regulatory Authorities has been the stepping stone of the principles of signal management in the new EU pharmacovigilance legislation.

Following his experience at the EMA, and before joining the OHE, Francois worked in the scientific advice team  at the National Institute for Health and Care Excellence (NICE). He advised companies on the clinical development of new technologies in various therapeutic areas (mainly oncology, cardiovascular, neurology ad orphan diseases) both in the framework of NICE, SEED (Shaping European Early Dialogue) and EMA-HTA parallel procedures (in collaboration with the CHMP Scientific Advice Working Party).

Francois has developed an interest in the practical, regulatory and methodological constraints of drug development of medicines pre- and also post-approval (including the conduct of post-authorisation efficacy studies) and the evidence generation for health technology appraisal purposes. For example, Francois has advised companies on the issues associated with the conduct of (non-comparative) single arm trials and the minimisation of biases associated with the use of external (non-concomitant) controls and on the issues associated with the conduct of cost-utility analyses using extrapolations based on non-inferiority studies.

He has also advised companies selected for the adaptive licensing pilot (and the issues associated with the use of observational or real world evidence after conditional approval), and was involved in the IMI ADAPT-SMART project. Francois has developed and maintained the NICE scientific advice database and he has performed an analysis of the scientific requests in which NICE was involved since 2009 (publication submitted to Nature Reviews: Drug Discovery, presented at the ISPOR meeting in Amsterdam, 2014)4.

Francois holds a doctorate in pharmacy, a post-graduation diploma in hospital pharmacy and public health and a MSc in molecular pharmacochemistry, experimental pharmacology and metabolism (Université René Descartes, Paris V, France). Francois also holds a MSc in applied statistics (Birkeck College, University of London, England).

References:

1. Maignen, F., Hauben, M., Tsintis, P., 2010. Modelling the time to onset of adverse reactions with parametric survival distributions: a potential approach to signal detection and evaluation. Drug Saf, May 1;33(5):417-34.

2. Maignen, F., Hauben, M., Hung, E., Van Holle, L., Dogne, J.M., 2014. A conceptual approach to the masking effect of measures of disproportionality.  Pharmacoepidemiol Drug Saf, Feb;23(2):208-17.

3. Maignen, F., Hauben, M., Hung, E., Van Holle, L., Dogne, J.M., 2014. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. Pharmacoepidemiol Drug Saf, Feb;23(2):195-207.

4. Maignen, F., Osipenko, L., Gajraj, E., Chivers, R., 2014. Trends in early engagement between industry and HTA: Analysis of scientific advice service provided by NICE since 2009. Value in Health, Nov;17(7):A441.

Related News

IRA-course-graphic-for-website-news-FINAL-1
  • News
  • May 2023

New free educational program launched – Explaining the U.S. Inflation Reduction Act

Read more
Group 11119
  • News
  • February 2023

Applications open for MSc Fellowship Programme 2023

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • July 2022

OHE is Leading Research to Develop an EQ-5D ‘Bolt-on’ for Hearing

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!